Skip to main content
Pain Management logoLink to Pain Management
. 2021 Jun 9;11(5):571–581. doi: 10.2217/pmt-2020-0089

The effect of obesity on pain severity and pain interference

Jade I Basem 1, Robert S White 1, Stephanie A Chen 2, Elizabeth Mauer 3, Michele L Steinkamp 1, Charles E Inturrisi 4, Lisa R Witkin 1,*
PMCID: PMC9008601  PMID: 34102863

Abstract

Aim:

Obesity is one of the most prevalent comorbidities associated with chronic pain, which can severely interfere with daily living and increase utilization of clinical resources. We hypothesized that a higher level of obesity, measured by BMI, would be associated with increased pain severity (intensity) and interference (pain related disability).

Materials & methods:

Participant data was pulled from a multisite chronic pain outpatient database and categorized based on BMI.

Results:

A total of 2509 patients were included in the study. We found significant differences between BMI groups for all pain severity scores (worst, least, average, current) and total pain interference score. Obese patients had significantly higher scores than normal weight patients.

Conclusion:

We found obesity to be associated with increased pain severity and pain interference.

Keywords: : chronic pain, obesity, outcome assessment, pain management, pain medicine


The Institute of Medicine estimates that 100 million US adults are affected by chronic pain, which costs the nation $635 billion yearly in medical treatment and lost productivity [1]. Pain is a common experience for the general population, as 11.2% of adults report daily pain symptoms [2]. Pain is the most common reason patients seek medical attention with approximately one-fifth of ambulatory medical care associated with pain as a primary symptom or diagnosis [3,4]. The experience of pain is complex, as chronic pain is a multidimensional hierarchical construct that consists of both the sensation of pain severity and interference in engagement with activities [5]. In addition, a threshold effect occurs where low levels of pain intensity are not associated with functional interference; however, higher levels of pain intensity increase the probability of interference in a nonlinear fashion [5–7].

One of the prevalent comorbidities that is commonly associated with chronic pain is obesity [8]. Data from the National Health and Nutrition Examination Survey from 2015 to 2016 demonstrates that 39.8% of US adults were obese [9]. The presence of obesity is associated with an increase in self-reported bodily pain measures and pain related disability, a decrease in psychological well-being, and reduced physical functioning [10–12]. The relationship between pain and obesity is likely multidirectional and multifactorial, including central pain and inflammatory pathways [13–15]. Provider prescriptions of nonsteroidal anti-inflammatory agents used to treat pain are higher among patients with obesity [16,17].

Given the prevalence of obesity in the general and chronic pain populations and its effect on clinical outcomes, it is important to understand how obesity affects the validated pain outcomes commonly used in clinical practice, including pain severity and pain interference. Previous research has elucidated higher pain scores in female, osteoarthritic and postoperative patients with obesity. However, these studies are often limited by small or homogeneous cohorts or examine outcomes that are not commonly used by chronic pain providers in a clinical setting [18–22]. No major study to date has analyzed the impact that obesity has on both pain severity and interference scores in a general and diverse chronic pain population. Herein, we seek to further explore the association of obesity as a risk factor for pain related outcomes. Outcomes of interest include pain severity and pain interference. We hypothesized that a higher level of obesity, as measured by BMI, would be associated with increased pain severity and pain interference.

Materials & methods

Patient population

We collected data from a longitudinal observational cohort of chronic pain outpatients seen in the Weill Cornell Medicine (WCM) pain medicine clinic from 8 July 2011 to 17 October 2016. These patients are part of a larger tri-institutional chronic pain database herein referred to as The Registry, which encompasses Pain Services data from WCM, Hospital for Special Surgery and Memorial Sloan-Kettering Cancer Center (MSKCC), NY, USA. The Registry design, enrollment procedures, data collection and analysis have been previously described [23]. A data sharing agreement exists between WCM and the Health System Innovation and Research Program, University of Utah School of Medicine, UT, USA, who maintain the database and assist with the data analysis. Health System Innovation and Research Program merges the coded Patient Reported Outcomes data in Webcore with data captured in EPIC, our electronic health record system, to form a complete coded limited dataset for The Registry [23]. While patient identifiers are removed, the coded data contains encounter dates, and therefore the data represents a limited dataset according to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rules. Patient data is collected under standard of care and is part of a quality improvement program.

The inclusion criteria for this study was all chronic pain patients, as defined by at least one clinic attendance. If multiple visits had data recorded, the first entry was the value used in analysis, including BMI. The original exclusion criteria for The Registry was absence of a chronic pain diagnosis, but for this study the exclusion criteria also included patients without BMI data and without a specific type of chronic pain diagnosis for the encounter [23]. The ICD-9 code associated with the first visit was used as the primary diagnosis.

Patient specific factors and process factors were obtained for each patient at each encounter. These factors included: demographics (age, sex, marital status, ethnicity, language, religion and payor), vitals (height, weight, blood pressure, temperature, pulse rate), diagnoses, current procedural terminology (CPT) codes, medications and the survey data which included the pain severity and pain interference scores. BMI was calculated as weight in kilograms divided by the square of height in meters. Participants were categorized into three groups based on BMI: underweight (BMI <18.5), normal weight (BMI = 18.5–24.99), overweight (BMI = 25–29.9) and obese (BMI ≥30); the normal weight category was used as the reference in all models.

During each outpatient pain clinic encounter, pain information was collected using the Brief Pain Inventory short form. The Brief Pain Inventory short form is a validated tool that assesses the presence of pain; pain severity, pain interference, percentage of relief provided by pain treatments or medications (0–100%), and the location of pain at 22 prespecified sites assessed over a 24-h recall period [24]. Patients describe their pain severity on a scale from 0 (“No Pain”) to 10 (“Pain as bad as you can imagine”) when their pain is at its worst, least, on average and if they are experiencing pain right now [7]. Pain interference is measured on seven daily functions, including general activity, mood, walking ability, normal work (includes both work outside the house and housework), relations with other people, sleep and enjoyment of life. Each pain interference measure is assessed through a rating scale from 0 (“Does not Interfere”) to 10 (“Completely Interferes”).

Estimating opioid use, dosage & duration

Opioid medications that were being taken and prescribed at each encounter were abstracted from EPIC. For patients included in the Registry, we captured all the opioids recorded for each encounter backward to 1 November 2010 (this date was specified as when clinicians were required to perform medication reconciliation in EPIC and therefore represents the most reliable data). Resultantly, opioid duration was measured from 1 November 2010 to 1 September 2016, including opioid use prior to entry into the Registry. Based on a discussion with the pain clinicians on patient opioid prescription filling practices, we looked back at least 45 days from their clinic visit for a schedule 2 opioid prescription or refill. We excluded patients receiving intrathecal opioids from this analysis.

Statistical analysis

Statistical analyses were performed using R Version 3.5.3 (Vienna, Austria) [25]. Bivariate analyses were performed to compare pain outcomes by demographic/clinical patient characteristics as well as to compare demographic/clinical patient characteristics by BMI groups (underweight, normal, overweight and obese). Bivariate tests included independent two-sample t-tests, Analysis of Variance (ANOVA) or Chi-squared/Fisher’s Exact tests, as appropriate. Nonparametric equivalents were used for violations of normality.

To examine the effect of BMI on pain severity and pain interference we fit multivariable linear regression models to our data; regression coefficients along with their 95% CIs were reported. We developed separate models for each of the four pain severity scores (worst, least, average and current) and for total pain interference with the additional inclusion of pain severity as a covariate. All models adjusted for demographic and clinical variables available and considered relevant (age, pain procedure within 45 days prior, opioids prescribed within 45 days prior and diagnosis). All statistical tests were two-sided with statistical significance assigned at an alpha level of 0.05.

Results

A total of 2509 patients were included in the study. The cohort’s median age was 59 years, median BMI was 27 kg/m2, and the most common pain diagnosis category was musculoskeletal pain (77%). About 20% of the patients received a pain procedure within 45 days prior to the pain clinic encounter. Pain procedures could not be further stratified in our dataset, but include the most commonly performed minimally invasive, image-guided injections including epidural steroid injections, facet injections and joint injections, for example. Half of the patients (53%) received an opioid prescription within 45 days prior. Differences between BMI groups are shown in Table 1. Some statistical significance represents underlying differences in the spread of pain scores, as shown through the range. Bivariate tests revealed significant differences between BMI groups for all pain severity scores and for total pain interference score (Table 2). Additional covariates, such as ethnicity, religion and more granular comorbidities were omitted from the data analysis due to the lack of consistent available information in our dataset.

Table 1. . Differences between BMI groups.

  BMI <18.5 18.5–24.99 BMI 25–29.99 BMI ≥30 p-value n
Weight 106 (98.8; 118) 136 (122; 153) 171 (155; 190) 215 (190; 243) 0 2509
Height 65.3 (63.7; 69.0) 65.5 (63.0; 68.7) 66.1 (63.0; 70.0) 65.5 (63.9; 69.0) <0.001 2509
Age (continuous) 52.2 (36.8; 69.5) 58.2 (42.2; 72.2) 60.7 (49.7; 71.3) 59.1 (49.4; 68.6) 0.003 2509
Age (categorical)         <0.001 2509
 18–44 25 (36.8%) 249 (28.8%) 152 (18.1%) 120 (16.3%)    
 45–64 23 (33.8%) 283 (32.7%) 362 (43.0%) 364 (49.6%)    
 65+ 20 (29.4%) 334 (38.6%) 327 (38.9%) 250 (34.1%)    
Sex         <0.001 2509
 Female 57 (83.8%) 561 (64.8%) 417 (49.6%) 452 (61.6%)    
 Male 11 (16.2%) 305 (35.2%) 424 (50.4%) 282 (38.4%)    
Payor         <0.001 2373
 Medicare 20 (31.2%) 303 (36.8%) 307 (38.6%) 254 (36.9%)    
 Medicaid 7 (10.9%) 105 (12.7%) 134 (16.8%) 168 (24.4%)    
 Commercial 37 (57.8%) 416 (50.5%) 355 (44.6%) 267 (38.8%)    
Ethnic group           2509
 African American 0 (0.00%) 1 (0.12%) 0 (0.00%) 1 (0.14%)    
 Asian/PA 0 (0.00%) 1 (0.12%) 0 (0.00%) 0 (0.00%)    
 Caucasian 0 (0.00%) 1 (0.12%) 1 (0.12%) 0 (0.00%)    
 Declined 26 (38.2%) 334 (38.6%) 329 (39.1%) 220 (30.0%)    
 Hispanic 2 (2.94%) 54 (6.24%) 85 (10.1%) 113 (15.4%)    
 Multiracial 0 (0.00%) 2 (0.23%) 1 (0.12%) 0 (0.00%)    
 Not Hispanic 38 (55.9%) 427 (49.3%) 391 (46.5%) 357 (48.6%)    
 Null 0 (0.00%) 1 (0.12%) 0 (0.00%) 0 (0.00%)    
 Unknown 2 (2.94%) 45 (5.20%) 34 (4.04%) 43 (5.86%)    
Pain procedure with 45 days prior         0.884 2509
 No 57 (83.8%) 691 (79.8%) 675 (80.3%) 588 (80.1%)    
 Yes 11 (16.2%) 175 (20.2%) 166 (19.7%) 146 (19.9%)    
Pain procedure with 45 days after         0.804 2509
 No 56 (82.4%) 680 (78.5%) 652 (77.5%) 576 (78.5%)    
 Yes 12 (17.6%) 186 (21.5%) 189 (22.5%) 158 (21.5%)    
Opioid medication within 45 days prior         0.002 2509
 No 25 (36.8%) 431 (49.8%) 410 (48.8%) 306 (41.7%)    
 Yes 43 (63.2%) 435 (50.2%) 431 (51.2%) 428 (58.3%)    
IR opioid medications within 45 days prior       <0.001 2509
 No 26 (38.2%) 463 (53.5%) 435 (51.7%) 321 (43.7%)    
 Yes 42 (61.8%) 403 (46.5%) 406 (48.3%) 413 (56.3%)    
ER opioid medications within 45 days prior       0.064 2509
 No 51 (75.0%) 738 (85.2%) 730 (86.8%) 627 (85.4%)    
 Yes 17 (25.0%) 128 (14.8%) 111 (13.2%) 107 (14.6%)    
Pain severity and interference            
 Worst pain, 24 h 8.00 (6.00; 9.00) 7.00 (5.00; 9.00) 8.00 (6.00; 9.00) 8.00 (6.00; 9.00) <0.001 2425
 Least pain, 24 h 5.00 (3.00; 7.00) 4.00 (2.00; 6.00) 4.00 (2.00; 7.00) 5.00 (2.00; 7.00) <0.001 2415
 Average pain, 24 h 6.00 (4.25; 8.00) 6.00 (4.00; 7.00) 6.00 (4.00; 8.00) 6.00 (5.00; 8.00) <0.001 2371
 Pain now-current 6.50 (4.00; 8.00) 5.00 (3.00; 7.00) 6.00 (3.00; 8.00) 6.00 (4.00; 8.00) <0.001 2370
 General activity 7.00 (5.00; 9.00) 6.00 (4.00; 8.00) 6.00 (4.00; 8.00) 7.00 (5.00; 9.00) <0.001 2345
 Mood 7.00 (4.00; 9.00) 6.00 (2.00; 8.00) 5.00 (3.00; 8.00) 6.00 (3.00; 8.00) 0.003 2330
 Walking 6.00 (3.00; 9.00) 5.00 (2.00; 8.00) 6.00 (3.00; 8.00) 7.00 (4.00; 9.00) <0.001 2339
 Normal work 7.00 (5.00; 9.00) 6.00 (4.00; 8.00) 7.00 (4.00; 9.00) 7.00 (5.00; 9.00) <0.001 2315
 Relations with others 5.00 (1.25; 7.00) 4.00 (0.00; 7.00) 4.00 (0.00; 7.00) 5.00 (0.00; 7.00) 0.035 2294
 Sleep 6.50 (3.00; 8.00) 5.00 (1.00; 8.00) 5.00 (2.00; 8.00) 6.00 (3.00; 9.00) 0.003 2318
 Enjoyment of life 8.00 (5.00; 9.00) 6.00 (3.00; 8.00) 7.00 (4.00; 8.00) 7.00 (5.00; 9.00) <0.001 2297
 Interference total score 6.29 (5.00; 7.71) 5.43 (3.14; 7.43) 5.71 (3.71; 7.43) 6.46 (4.14; 8.00) <0.001 2359
Diagnosis category           2509
 Back pain 14 (20.6%) 238 (27.5%) 268 (31.9%) 218 (29.7%)    
 Extremity pain 12 (17.6%) 102 (11.8%) 102 (12.1%) 105 (14.3%)    
 Head-mouth pain 2 (2.94%) 17 (1.96%) 16 (1.90%) 8 (1.09%)    
 Inflammatory pain 2 (2.94%) 6 (0.69%) 5 (0.59%) 6 (0.82%)    
 Myofascial pain 5 (7.35%) 75 (8.66%) 36 (4.28%) 39 (5.31%)    
 Neuropathic 8 (11.8%) 98 (11.3%) 109 (13.0%) 90 (12.3%)    
 Osteoarthrosis pain 5 (7.35%) 55 (6.35%) 64 (7.61%) 63 (8.58%)    
 Pelvic-abdominal pain 9 (13.2%) 57 (6.58%) 45 (5.35%) 21 (2.86%)    
 Radicular pain 6 (8.82%) 181 (20.9%) 166 (19.7%) 147 (20.0%)    
 Unclear/unknown 5 (7.35%) 37 (4.27%) 30 (3.57%) 27 (5.04%)    
Diagnosis category         0.001 2509
 Musculoskeletal 44 (64.7%) 657 (75.9%) 641 (76.2%) 578 (78.7%)    
 Neuropathic 8 (11.8%) 98 (11.3%) 109 (13.0%) 90 (12.3%)    
 Other 11 (16.2%) 74 (8.55%) 61 (7.25%) 29 (3.95%)    
 Unclear/unknown 5 (7.35%) 37 (4.27%) 30 (3.57%) 37 (5.04%)    

ER: Extended release; IR: Immediate release.

Table 2. . Multivariable model results.

    Pain severity (worst 24 h) Pain severity (least 24 h) Pain severity (average 24 h) Pain severity (current) Pain interference
    Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value Estimate (95% CI) p-value
Sex Sex (male) -0.578
(-0.782, -0.373)
0.000 -0.621
(-0.861, -0.382)
0.000 -0.619
(-0.819, -0.420)
0.000 -0.678
(-0.913, -0.442)
0.000 -0.212
(-0.379, -0.046)
0.013
Payor status Medicaid 0.541 (0.227, 0.856) 0.001 1.390
(1.021, 1.759)
0.000 0.736
(0.428, 1.044)
0.000 0.896
(0.533, 1.259)
0.000 0.113
(-0.143, 0.369)
0.388
  Commercial -0.438
(-0.700, -0.178)
0.001 -0.339
(-0.646, -0.033)
0.030 -0.476
(-0.731, -0.221)
0.000 -0.418
(-0.719, -0.117)
0.007 -0.179
(-0.390, 0.033)
0.098
BMI Underweight 0.296
(-0.328, 0.919)
0.353 0.760 (0.025, 1.495) 0.043 0.406
(-0.196, 1.009)
0.186 0.689
(-0.023, 1.401)
0.058 0.304
(-0.201, 0.810)
0.238
  Ref = normal weight
  Overweight 0.198
(-0.043, 0.439)
0.108 0.434 (0.151, 0.718) 0.003 0.189
(-0.047, 0.426)
0.117 0.170
(-0.108, 0.449)
0.231 0.229
(0.033, 0.425)
0.022
  Obese 0.339 (0.088, 0.589) 0.008 0.615 (0.321, 0.908) 0.000 0.355
(0.111, 0.599)
0.004 0.611 (0.322, 0.900) 0.000 0.355 (0.152, 0.558) 0.001
Age   -0.004
(-0.011, 0.004)
0.304 -0.001
(-0.010, 0.008)
0.809 -0.001
(-0.008, 0.007)
0.887 -0.011
(-0.019, -0.002)
0.014 -0.020
(-0.026, -0.014)
0.000
Pain procedure within 45 days prior 0.064
(-0.181, 0.309)
0.609 -0.083
(-0.370, 0.205)
0.573 -0.084
(-0.324, 0.156)
0.492 -0.041
(-0.324, 0.242)
0.775 -0.027
(-0.225, 0.171)
0.787
Opioid prescription within 45 days prior 0.661
(0.459, 0.863)
0.000 0.580 (0.343, 0.817) 0.000 0.523 (0.326, 0.721) 0.000 0.676 (0.443, 0.909) 0.000 0.418 (0.253, 0.584) 0.000
Diagnosis Ref = musculoskeletal
  Neuropathic 0.108
(-0.201, 0.416)
0.494 0.058
(-0.304, 0.420)
0.754 0.076
(-0.224, 0.376)
0.619 0.097
(-0.259, 0.453)
0.593 -0.158
(-0.408, 0.092)
0.217
  Other 0.161
(-0.230, 0.551)
0.420 -0.318
(-0.775, 0.139)
0.172 -0.045
(-0.427, 0.337)
0.818 -0.343
(-0.793, 0.107)
0.135 -0.295
(-0.609, -0.018)
0.065
  Unclear/unknown -0.172
(-0.653, 0.309)
0.483 -0.192
(-0.754, 0.371)
0.504 -0.061
(-0.526, 0.404)
0.797 -0.188
(-0.739, 0.363)
0.504 0.350
(-0.039, 0.739)
0.078
  Worst pain 0.679 (0.646, 0.712)1 0.000

–: No data.

For each multivariable model looking at pain severity (as either the worst, least, average, or current pain within the past 24 h), patients with obesity demonstrated significantly higher scores than normal weight patients after controlling for age, pain procedure within the 45 days prior to the pain clinic encounter, opioid prescription within the 45 days prior, diagnosis category, sex and payor status. Specifically, patients with obesity had an average 0.339 higher severity score at their worst pain within the past 24 h, 0.615 at their least pain within the past 24 h, 0.355 at their average pain in the past 24 h and 0.611 at their current pain than patients within the normal weight range. Similarly, for the multivariable model looking at overall pain interference, patients with obesity demonstrated significantly higher scores than normal weight patients after controlling for the same factors in addition to pain severity (as measured as the worst pain in the past 24 h). Specifically, patients with obesity had an average 0.355 higher overall pain interference score than patients without obesity.

Confirming our assumption, pain severity (as measured as the worst pain in the past 24 h) was significantly associated with overall pain interference; specifically, overall pain interference increased on average by 0.679 points for each additional point higher in worst pain severity.

Underweight patients and overweight patients also showed higher scores for least pain in 24 h (0.760 and 0.434, respectively) that reached significance compared with patients of normal BMI. Additionally, underweight patients trended toward significance for the pain severity model (p = 0.058) and overweight patients had a significant difference for the pain interference model (p = 0.022), both compared with patients of normal BMI.

Opioid prescription was statistically significant for each pain severity and pain interference outcome used in multivariable modeling (p < 0.0001 for all outcomes). 58.3% of patients with obesity and 63.2% of underweight patients were prescribed opioid medications within 45 days prior compared with only 50.7% of normal weight patients (p = 0.001), with all BMI groups being more likely to take pain medications than not. Differences between BMI groups also existed when looking specifically at immediate-release (IR) opioid medications and extended-release (ER) opioid medications prescribed. A total of 56.3% of patients with obesity and 61.8% of underweight patients were prescribed IR opioid medications compared with 46.5 and 48.3% of normal and overweight patients (p < 0.001), respectively. About 14% of both obese, normal and overweight patients were prescribed ER opioid medications compared with 25% of underweight patients (p = 0.041).

Discussion

Pain severity & interference

Our study showed that pain clinic patients with obesity experience higher pain severity and pain interference scores than normal weight patients. Our findings corroborate prior literature that shows that obesity is a risk factor for chronic pain [26–31] and demonstrates that obesity is an independent risk factor for experiencing more pain severity and pain that may interfere with patients’ daily function. Heim et al. reported that in a population of older adults, patients with obesity were more likely to develop pain, and that the frequency of pain increased more drastically with increased BMI, especially for women [32]. Their study found that, regardless of weight changes, someone with a higher BMI is more likely to longitudinally develop chronic pain [32].

Pain severity

Our study found that obesity was related to pain severity. Patients’ rating of worst pain in the last 24 h was statistically significant, with increased pain severity found in patients with obesity compared with the normal patients. Overweight and underweight patients did not have a statistically significant difference compared with normal patients in multivariable modeling of worst pain in the last 24 h. Obesity as a risk factor for pain severity has been found in many other studies, ranging from adolescents to geriatric populations [30,31,33,34]. Chronic pain development in an obese population, particularly morbidly obese (BMI >35), after a motor vehicle accident had a significant effect on increasing pain severity during multiple follow-up visits within a year [22].

However, some studies have disputed the relationship between pain severity and obesity [19,35]. Taspinar et al. did not find obesity to influence pain severity for university students with nonspecific back pain. However, this study included only university students, which limits its generalizability to the wider chronic pain population, which includes patients of a larger age range.

Looking at the underweight population, the literature agrees with our finding of a trend toward increased current pain severity in the underweight population compared with the normal group [36]. Previously, this has also influenced the prescription of opioid medications for pain relief, specifically in cancer populations, but the true clinical relevance has yet to be determined. A recent study found a j-curve with BMI for pain presence and pain intensity, so this could be the phenomenon observed in our results as well [37].

Pain interference

Pain severity is related to pain interference, as it is not unexpected that higher levels of pain intensity would have more drastic effects on functioning [5]. In our study, pain interference scores increased with increased ratings of worst pain in the last 24 h. Pain severity and frequency has been shown to directly predict pain interference and quality of life [38–40]. Of note, our findings contradict with several studies that did not find an association between pain severity and pain interference [19]. This finding could be due to a threshold effect that occurs where low levels of pain intensity are not associated with functional interference and where higher levels of pain intensity increase the probability of higher levels of pain interference in a nonlinear fashion [5–7].

In our study, patients with obesity had higher pain interference than normal weight patients. This follows previous trends finding that patients with obesity have a higher frequency of pain interference and more severe disability from pain [19,29,34,39]. Our finding of overweight patients also being statistically significantly higher for values of their pain interference further supports our hypothesis of weight influencing pain interference. Only one study found obesity to be independent of pain interference scores [18].

Sex

Females had consistently worse pain for all pain severity categories and pain interference totals both in the bivariate analyses and multivariable models, which is consistent with prior literature findings [32,34,41]. Sensitivity analyses showed that sex did not impact the relationship between BMI and pain severity or pain interference.

Payor group

Pain severity and pain interference was also impacted by payor status, such that these scores were worse for Medicare and Medicaid patients compared with commercially insured patients. While the observed scores were higher for Medicaid patients compared with Medicare, these differences were not statistically significant. This finding is not surprising, as Medicare patients may be older or have more significant health conditions compared with commercially insured patients; however, the finding regarding Medicaid patients may be due to those patients receiving specialty care later in their diseases progression and presenting with more severe underlying disease, or suggest a health disparity that warrants further investigation. As with sex, these payor differences did not change the relationship of BMI with pain severity and pain interference in multivariable modeling.

Limitations

Our study is limited by the retrospective, multi-institutional data collected primarily from tertiary care centers, and the high prevalence of musculoskeletal pain in our population. Seventy-seven percent of all participants in this study had a diagnosis of musculoskeletal pain, and 79% of patients with obesity diagnosed with that as well, being only slightly higher than the normal (75.9%) and overweight category (76.2%) and significantly higher than the underweight group (64.7%). The data did not include information about the distribution of fat. Previous literature often restricted cohort populations to those with specific types of pain, like musculoskeletal pain, since its development has been more easily associated with obesity [33,34,37,41]. Musculoskeletal pain has also been connected with more pain locations, which is further increased within an obese population [34,41]. Back pain specifically was the most frequent diagnosis within our population, which has previously been linked to obesity as well [30]. Osteoarthritis, however, was less common in this population and that has previously been associated with significant increased pain in obesity studies [37]. While a diagnosis of musculoskeletal pain may influence obesity and pain severity scores, it is an extremely prevalent pain diagnosis with clinical implications in both our population and the general population, and thus could not be ignored. Our data suggests that even with chronic pain diagnoses not related to musculoskeletal pain, the same trends with obesity and increased pain and pain interference are found.

Our study was also limited by the categorization of weight. For our study, obesity was defined as anyone with a BMI greater than or equal to 30. Further stratification of this obese category has shown trends that indicate greater pain in the severely obese. For McCarthy et al., the severely obese, or those with a BMI of at least 35, were associated with four-times the probability of having chronic pain compared with normal patients, whereas those with BMI = 30–34.99 were only twice as likely [34]. This stratification more drastically shows the impact that obesity poses on the experience of chronic pain. Deyo et al. also showed that for those in the top 20%, the prevalence of pain has been found to be significantly higher than those in the bottom 20% of the obese category [28]. While we did not stratify further our obese category, our separation of overweight and obese from normal weight patients does show that patients with obesity had consistently higher pain severity and interference scores than overweight patients. In addition, our study highlights that underweight patients, even with a smaller percentage of musculoskeletal pain diagnoses, similarly have increased pain severity and pain interference, highlighting the importance of BMI in both directions.

Our study only included patients that visited the outpatient pain clinics included in The Registry at least once and who had BMI data and a diagnosis for the encounter. The survey data analyzed was that of the first survey in the registry for each patient. While the first available BMI value was used as well, this did not consistently align with the first full survey dataset since patients often had multiple pain clinic encounters. The inconsistency of complete data sets also meant that we could not compare baseline visits to follow-up visits. By identifying patients retrospectively, we could not follow their progress over more visits longitudinally. Information such as BMI changes and prospective associations were thus unable to be calculated. A recent systematic review suggests that patients with chronic pain and obesity have worse pain management results, which could be implicated in our findings of pain prevalence, severity and interference [30]. In addition, while The Registry is a multisite database, it gathers information solely from New York City-based sites, which could limit the generalizability of our results.

In addition, The Registry database was limited by missing information regarding some sociodemographic data (i.e., language, marital status, religion and ethnic group), occupation information, and by the categorization of comorbidities within the electronic medical record making it difficult to analyze. Specifically, our study was not able to capture the prevalence of psychiatric comorbidities within our chronic pain population. Many other studies have found that this dramatically impacts both obesity and pain, often increasing the likelihood or severity of both [9–11,26,27,34,42,43]. Further research is warranted to assess the role of psychiatric comorbidities and occupation, as well as sociodemographic difference, on pain interference and severity within a chronic pain population.

Conclusion

Our study demonstrated that BMI is associated with statistically significant changes in pain severity and interference as well as opioid prescriptions from real-world data in a large academic pain center that includes not just musculoskeletal pain, but a diverse number of pain conditions receiving multimodal treatments, including interventions. The management of chronic pain is multifaceted and complex, particularly in the obese chronic pain population. Our study suggests that these patients’ chronic pain is characterized not only by higher pain severity, but also greater interference with activities of daily living. While these findings are statistically significant, the clinical significance and implication for patient care remains to be seen, but suggests that BMI has a significant effect and could highlight the need for improved individualized treatment strategies, including counseling patients about their BMI, health maintenance, and setting reasonable expectations regarding physical functioning and prognosis. Further prospective research is warranted to understand the relationship between reducing BMI and pain interference scores, as well as understanding the impact in the underweight population, and the influence of sociodemographic factors.

Future perspective

In the field of pain medicine, we speculate that treatment options will continue to become more individualized, particularly in recognizing and treating obesity as a comorbidity of chronic pain. Current research, including our own, demonstrates that obesity is a risk factor for increased pain severity and pain interference on quality of life metrics. Incorporating obesity status and other individualized concerns into a patient's medical history and plan could greatly influence clinical prognosis and chosen pain management treatments.

Summary points.

  • Pain severity and pain interference has a statistically significant association with BMI, specifically obesity as well as opioid prescriptions.

  • The management of chronic pain is multifaceted and complex, particularly in the obese chronic pain population.

  • Our study suggests that these patients’ chronic pain is characterized not only by higher pain severity, but also greater pain interference, including with activities of daily living.

  • We believe that this relationship is multifactorial and bidirectional, and that pain physicians should consider the impact of obesity when developing an individualized pain management treatment strategy.

  • Further prospective research is warranted to understand the relationship between BMI and pain severity as well as pain interference.

Acknowledgments

The authors would like to thank the Weill Cornell Medicine Department of Anesthesiology for their support.

Footnotes

Financial & competing interests disclosure

CE Inturrisi receives compensation as described in a 2017 license agreement between CE Inturrisi (and P Manfredi) and Relmada Therapeutics, Inc. for the development of compounds (including d-methadone) for the treatment of depression. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved. This study was approved by the Institutional Review Board and Clinical Study Evaluation Committee of Weill Cornell Medicine.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

  • 1.Gaskin DJ, Richard P. The economic costs of pain in the United States. J. Pain 13(8), 715–724 (2012). [DOI] [PubMed] [Google Scholar]
  • 2.Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Mil. Med. 181(5), 397–399 (2016). https://academic.oup.com/milmed/article/181/5/397/4158290 [DOI] [PubMed] [Google Scholar]
  • 3.Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain 16(8), 769–780 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Daubresse M, Chang HY, Yu Y et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med. Care 51(10), 870–878 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.White RS, Jiang J, Hall CB et al. Higher perceived stress scale scores are associated with higher pain intensity and pain interference levels in older adults. J. Am. Geriatr. Soc. 62(12), 2350–2356 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the effects of amputation pain: further clarification of the meaning of mild, moderate, and severe pain. Pain 91(3), 317–322 (2001). [DOI] [PubMed] [Google Scholar]
  • 7.Woo A, Lechner B, Fu T et al. Cut points for mild, moderate, and severe pain among cancer and non-cancer patients: a literature review. Ann. Palliat. Med. 4(4), 176–183 (2015). [DOI] [PubMed] [Google Scholar]
  • 8.Okifuji A, Hare BD. The association between chronic pain and obesity. J. Pain Res. 8, 399–408 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]; • Okifuji and Hare found in their literature review that patients with obesity often also had chronic pain and that there is a complex relationship between the way that these two comorbidities impact each other, such that they both have been found to be risk factors for the other but are impacted by many other factors as well.
  • 9.Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief (288), 1–8 (2017). [PubMed] [Google Scholar]
  • 10.Arnstein P, Caudill M, Mandle CL, Norris A, Beasley R. Self efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients. Pain 80(3), 483–491 (1999). [DOI] [PubMed] [Google Scholar]
  • 11.Zdziarski LA, Wasser JG, Vincent HK. Chronic pain management in the obese patient: a focused review of key challenges and potential exercise solutions. J. Pain Res. 8, 63–77 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hitt HC, Mcmillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of obesity and pain in a general population: results from the Southern Pain Prevalence Study. J. Pain 8(5), 430–436 (2007). [DOI] [PubMed] [Google Scholar]
  • 13.Briggs MS, Givens DL, Schmitt LC, Taylor CA. Relations of C-reactive protein and obesity to the prevalence and the odds of reporting low back pain. Arch. Phys. Med. Rehabil. 94(4), 745–752 (2013). [DOI] [PubMed] [Google Scholar]
  • 14.Schaible HG, Von Banchet GS, Boettger MK et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann. NY Acad. Sci. 1193, 60–69 (2010). [DOI] [PubMed] [Google Scholar]
  • 15.Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 361(1–3), 184–187 (2004). [DOI] [PubMed] [Google Scholar]
  • 16.Antonov KI, Isacson DG. Prescription and nonprescription analgesic use in Sweden. Ann. Pharmacother. 32(4), 485–494 (1998). [DOI] [PubMed] [Google Scholar]
  • 17.Counterweight Project T. The impact of obesity on drug prescribing in primary care. Br. J. Gen. Pract. 55(519), 743–749 (2005). [PMC free article] [PubMed] [Google Scholar]
  • 18.Anastas T, Colpitts K, Ziadni M, Darnall BD, Wilson AC. Characterizing chronic pain in late adolescence and early adulthood: prescription opioids, marijuana use, obesity, and predictors for greater pain interference. Pain Rep. 3(6), e700 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Marcus DA. Obesity and the impact of chronic pain. Clin. J. Pain 20(3), 186–191 (2004). [DOI] [PubMed] [Google Scholar]; • Marcus had a sample of almost 400 university pain clinic patients that completed questionnaires and were divided into different BMI categories. Their results indicate that BMI impacts disability but not pain severity.
  • 20.Eslami V, Katz MJ, White RS et al. Pain intensity and pain interference in older adults: role of gender, obesity and high-sensitivity C-reactive protein. Gerontology 63(1), 3–12 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Pazzianotto-Forti EM, Sgariboldi D, Rasera I Jr, Reid WD. Impact of pain in overweight to morbidly obese women: preliminary findings of a cross-sectional study. Physiotherapy 104(4), 417–423 (2018). [DOI] [PubMed] [Google Scholar]
  • 22.Mauck MC, Hu J, Sefton C et al. Obesity increases the risk of chronic pain development after motor vehicle collision. Pain 160(3), 670–675 (2019). [DOI] [PubMed] [Google Scholar]
  • 23.Mehta N, Inturrisi CE, Horn SD, Witkin LR. Using chronic pain outcomes data to improve outcomes. Anesthesiology Clin. 34, 395–408 (2016). [DOI] [PubMed] [Google Scholar]
  • 24.Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann. Acad Med. Singapore 23(2), 129–138 (1994). [PubMed] [Google Scholar]
  • 25.Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria: (2019). www.scirp.org/(S(351jmbntvnsjt1aadkposzje))/reference/ReferencesPapers.aspx?ReferenceID=2600003 [Google Scholar]
  • 26.Shi Y, Hooten WM, Roberts RO, Warner DO. Modifiable risk factors for incidence of pain in older adults. Pain 151(2), 366–371 (2010). [DOI] [PubMed] [Google Scholar]
  • 27.Ray L, Lipton RB, Zimmerman ME, Katz MJ, Derby CA. Mechanisms of association between obesity and chronic pain in the elderly. Pain 152(1), 53–59 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Deyo RA, Bass JE. Lifestyle and low-back pain. The influence of smoking and obesity. Spine 14(5), 501–506 (1989). [DOI] [PubMed] [Google Scholar]
  • 29.Rubin DI. Epidemiology and risk factors for spine pain. Neurol. Clin. 25(2), 353–371 (2007). [DOI] [PubMed] [Google Scholar]
  • 30.Narouze S, Souzdalnitski D. Obesity and chronic pain: systematic review of prevalence and implications for pain practice. Reg. Anesth. Pain Med. 40(2), 91–111 (2015). [DOI] [PubMed] [Google Scholar]; •• Narouze and Souzdalnitski completed a systematic literature review and found that people with obesity often also experienced chronic pain, and encouraged future research to continue looking at the interactions of these two conditions and of pain interference.
  • 31.Janke EA, Collins A, Kozak AT. Overview of the relationship between pain and obesity: what do we know? Where do we go next? J. Rehabil. Res. Dev. 44(2), 245–262 (2007). [DOI] [PubMed] [Google Scholar]; •• Janke et al. completed a literature review that supported the idea that obesity is a risk factor for chronic pain and that it is a complicated relationship to understand. They also pointed that many studies were lacking information on both pain interference and pain quality.
  • 32.Heim N, Snijder MB, Deeg DJ, Seidell JC, Visser M. Obesity in older adults is associated with an increased prevalence and incidence of pain. Obesity (Silver Spring) 16(11), 2510–2517 (2008). [DOI] [PubMed] [Google Scholar]
  • 33.Deere KC, Clinch J, Holliday K et al. Obesity is a risk factor for musculoskeletal pain in adolescents: findings from a population-based cohort. Pain 153(9), 1932–1938 (2012). [DOI] [PubMed] [Google Scholar]; • Deere et al. found that in their sample of over 3000 adolescents, those with obesity had increased odds of pain, and that those with specific types of pain diagnoses (such as any pain, knee pain and chronic regional pain) were also more likely to report increased pain severity.
  • 34.Mccarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in elderly people: results from the Einstein aging study. J. Am. Geriatr. Soc. 57(1), 115–119 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]; •• McCarthy et al. found that people with obesity were more likely to have chronic pain than normal patients, and the likelihood was further increased for people with severe obesity. They also found that women of their 840 sample were more likely to have chronic pain than men.
  • 35.Taspinar F, Taspinar B, Cavlak U, Celik E. Determining the pain-affecting factors of university students with nonspecific low back pain. J. Phys. Ther. Sci. 25(12), 1561–1564 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Moryl N, Bokhari A, Griffo Y et al. Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl. Cancer Med. 8(18), 7516–7522 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Higgins DM, Buta E, Heapy AA et al. The relationship between body mass index and pain intensity among veterans with musculoskeletal disorders: findings from the MSD cohort study. Pain Med. (2020) (Epub ahead of print). [DOI] [PMC free article] [PubMed] [Google Scholar]; • Higgens et al. found in their study of military veterans with musculoskeletal disorder diagnoses that increased BMI was highly prevalent in their sample and that it was associated with increased odds of pain. They also found a J curve between obesity and pain.
  • 38.Hunfeld JA, Perquin CW, Duivenvoorden HJ et al. Chronic pain and its impact on quality of life in adolescents and their families. J. Pediatr. Psychol. 26(3), 145–153 (2001). [DOI] [PubMed] [Google Scholar]
  • 39.Lamb SE, Guralnik JM, Buchner DM et al. Factors that modify the association between knee pain and mobility limitation in older women: the Women’s Health and Aging Study. Ann. Rheum. Dis. 59(5), 331–337 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]; • Lamb et al. looked at the pain interference of almost 800 women due to knee pain and found that obesity was a significant risk factor for increased pain interference along with being associated with more severe pain. They also found that pain severity impacted pain interference.
  • 40.Thomas JG, Pavlovic J, Lipton RB et al. Ecological momentary assessment of the relationship between headache pain intensity and pain interference in women with migraine and obesity. Cephalalgia 36(13), 1228–1237 (2016). [DOI] [PubMed] [Google Scholar]
  • 41.Adamson J, Ebrahim S, Dieppe P, Hunt K. Prevalence and risk factors for joint pain among men and women in the West of Scotland Twenty-07 study. Ann. Rheum. Dis. 65(4), 520–524 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Jordan KP, Thomas E, Peat G, Wilkie R, Croft P. Social risks for disabling pain in older people: a prospective study of individual and area characteristics. Pain 137(3), 652–661 (2008). [DOI] [PubMed] [Google Scholar]
  • 43.Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J. Pain 11(11), 1230–1239 (2010). [DOI] [PubMed] [Google Scholar]

Articles from Pain Management are provided here courtesy of Taylor & Francis

RESOURCES